Publications by authors named "Beate Moeckesch"
Article Synopsis
- This study examines the long-term effectiveness and immune responses of the recombinant zoster vaccine (RZV) in adults aged 50 and older, focusing on data collected 5 to 7 years after vaccination.
- Analysis included 7,413 participants, revealing a sustained efficacy rate against herpes zoster (HZ) of approximately 84% to 90% from both the start of follow-up and from the original trials, with stable results over the years.
- Immune responses, measured by antibody concentrations and specific T-cell frequencies, showed significant persistence, indicating that the benefits of RZV for older adults last at least 7 years post-vaccination.
Background: The immunogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when coadministered with a quadrivalent seasonal inactivated influenza vaccine (IIV4) was investigated in a phase 3, open-label, randomized clinical trial in adults aged ≥50 years.
Methods: Subjects were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant System) and IIV4 at day 0 followed by a second HZ/su dose at month 2 (coadministration group), or IIV4 at month 0 and HZ/su at months 2 and 4 (control group). The primary objectives were the HZ/su vaccine response rate in the coadministration group and the noninferiority of the antibody responses to HZ/su and IIV4 in the coadministration compared with the control group.